Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. — FDA Warning Letter, 2026-08-06: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded
TL;DR
At a glance: The FDA's Center for Drug Evaluation and Research issued a warning letter on August 6, 2026 to Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. (FEI 3012560989) for significant CGMP deviations in API manufacturing, including failure to conduct adequate process validation before distributing APIs to U.S. compounding pharmacies and inadequate master production and control records. The letter also cited the firm for failing to provide drug listing information in eDRLS for demecarium bromide and chlorambucil, rendering these drugs misbranded and prohibited from interstate commerce under sections 501, 502, and 510 of the FD&C Act.
Argus analysis
# FDA Warning Letter Analysis: Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.
**Company and Findings**
Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd., a Tianjin-based active pharmaceutical ingredient (API) manufacturer, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on August 6, 2026. The inspection identified significant deviations from Current Good Manufacturing Practice (CGMP) for APIs, rendering manufactured products adulterated under federal law. Additionally, the company failed to list two drugs—demecarium bromide and chlorambucil—in FDA's electronic Drug Registration and Listing System (eDRLS), making these products misbranded.
**Regulatory Citations and Implications**
The violations centered on four CGMP deficiencies. First, the company distributed APIs to U.S. compounding pharmacies without process validation, violating the foundational requirement to demonstrate reproducible manufacturing (21 CFR Part 211). Second, batch records lacked critical processing information and equipment details, preventing adequate monitoring of variations (21 CFR 211.188). Third, analytical test methods were not validated or verified for suitability, undermining data reliability for identity, strength, purity, and potency (21 CFR 211.194). Fourth, no documented stability testing program existed to confirm storage conditions and expiry dates (21 CFR 211.192). The drug listing violations involved failure to comply with section 510 of the FD&C Act and 21 CFR Part 207, prohibiting introduction of unlisted drugs into interstate commerce.
**Expected Response and Monitoring**
FDA requested detailed remediation plans addressing process validation timelines, comprehensive master batch records, method validation assessments, and retrospective stability studies. Compliance officers should monitor whether Tianjin Kilo submits adequate responses within typical FDA timeframes and whether the company implements independent audits as requested. Peer manufacturers should note that FDA has enforcement authority to restrict or seize products from non-compliant facilities and may initiate import detention procedures absent satisfactory corrective action.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. MARCS-CMS 731761 — August 06, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-26-110 Product: Drugs Recipient: Recipient Name Wenjun Liao Recipient Title General Manager Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. Room 609, Building 6, no. 6 Ziyuan Road Huayuan High-tech Industrial Park Tianjin Shi , 300384 China (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 6, 2026 WARNING LETTER Reference number: 320-26-110 To Wenjun Liao: This warning letter advises you of significant deviations identified during a U.S. Food and Drug Administration (FDA) review of your products, processes, and records. Promptly address the deviations described herein without delay, including ensuring that appropriate resources are allocated to fully address the deviations and prevent their recurrence. This is not intended to be an all-inclusive list of the deviations that exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address deviations may result in regulatory action without further notice. FDA Review Deviations were identified and documented during review of your drug manufacturing facility, Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd., FDA Establishment Identifier (FEI) 3012560989. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from drugs that are unsafe, ineffective, or of poor quality. Your facility is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our July 7, 2025 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility. This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B). In addition, violations were identified and documented during a review of your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS). Based on our review, you failed to provide drug listing information for your drugs demecarium bromide and chlorambucil. Failure to provide listing information for a drug in accordance with section 510 of the FD&C Act, 21 U.S.C. 360, is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). As a result of this failur…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. cited for?
- The FDA Warning Letter to Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.?
- FDA issued the letter (MARCS-CMS 731761) on 2026-08-06 and posted it publicly on fda.gov on 2026-08-18.
- Is the FDA warning letter to Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tianjin-kilo-pharmaceutical-sci-tech-co-ltd-731761-08062026.
- What does a "high" severity rating mean for this letter?
- High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. — FDA Warning Letter, 2026-08-06: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-tianjin-kilo-pharmaceutical-sci-tech-co-ltd-2026-08-06-cgmp
"Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. — FDA Warning Letter, 2026-08-06: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-tianjin-kilo-pharmaceutical-sci-tech-co-ltd-2026-08-06-cgmp.
Argus HQ Research. "Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. — FDA Warning Letter, 2026-08-06: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded." Digital Empire Holdings LLC. Accessed August 19, 2026. https://argushq.ai/fda/warning-letter/fda-wl-tianjin-kilo-pharmaceutical-sci-tech-co-ltd-2026-08-06-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_tianjin_kilo_pharmaceutical_sci_tech_co_ltd_2026_08_06_cgmp_2026,
title = {Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. — FDA Warning Letter, 2026-08-06: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-tianjin-kilo-pharmaceutical-sci-tech-co-ltd-2026-08-06-cgmp},
note = {Accessed: August 19, 2026}
}